Biotechnology
IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today shared findings via a poster ...
2024-12-10 10:00
1244
Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024
SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...
2024-12-10 08:30
1534
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients withHuntington's Disease Volumetric MRI measurement is also approved as exploratory study endpoint BOSTON, Dec. 10, 2024 /PRNewswire/ -- Skyhawk Therapeu...
2024-12-10 00:47
1383
2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)
NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of tinengotinib in combination with atezol...
2024-12-09 23:00
1629
Seoul National University Bundang Hospital Establishes the first "International PSP Research and Treatment Center" in Korea
* MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center * Tackling Global Challenges in an Aging Era… "Aspiring to become a global research and treatment hub for the rare neurodegenerative disease" SEOUL, South Korea, Dec. 9, 2024 /PRNe...
2024-12-09 22:00
2021
Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
* Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 * Appoints US-based Chief Commercial Officer, Andrew Udell * Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- A...
2024-12-09 21:00
1492
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment o...
2024-12-09 18:00
1088
MGI Tech's Innovative Sequencing Technology Drives Mangrove Conservation Efforts in Thailand
Link to Thailand's mangrove ecosystem conservation project video:
https://youtu.be/12xOTDxgMPw
2024-12-09 15:34
1723
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...
2024-12-09 10:40
1174
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...
2024-12-09 08:42
1020
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. * CS5001 is well tolerated in heavily...
2024-12-09 08:20
1562
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-12-09 08:00
1788
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, two prestigious benchmarks jointly compiled by FTSE Russell and the Taiwan S...
2024-12-07 08:57
3204
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations
BEIJING, Dec. 6, 2024 /PRNewswire/ -- Qi Biodesign, a biotechnology company pioneering next-generation genome editing technologies, announced the completion of its Series A funding round. The company has now raised a total of $75 million across its Seed, Series Pre-A, and Series A stages. The Seri...
2024-12-06 20:15
6690
Another star technology platform of the Sanyou AI-STAL family
——Introducing Sanyou Mrna Mab innovative antibody generation technology platform SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes h...
2024-12-06 18:30
1568
SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center
* SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 * Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ13731...
2024-12-06 09:00
1968
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in theAsia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sens...
2024-12-06 08:07
1766
IonOpticks' Custom Chromatography Column to Become Biognosys' Standard for High-Quality Proteomic Insights
MELBOURNE, Australia and ZURICH, Dec. 6, 2024 /PRNewswire/ -- Today, IonOpticks, a world leading provider of chromatography solutions, and Biognosys, a global leader in mass spectrometry-based proteomics contract research services, announce a long-term supply agreement. Under the agreement, IonO...
2024-12-06 05:00
1995
Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services
* Mission Launched via SpaceX CRS-31; Experiment Now Underway on the ISS
* Collaboration Aims to Enhance Healthspan on Earth and Improve Astronaut
Health in Space
* IM8, a new premium supplements brand launched officially on November 18th on
IM8health.com
2024-12-05 21:30
2169
Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.
* First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). * FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devicesthat could provide more effe...
2024-12-05 21:03
1571
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 307 media titles]
2024-12-19 17:56
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 305 media titles]
2024-12-20 18:11
MediSun Energy Joins the Abu Dhabi Sustainable Finance Declaration, Reinforcing Commitment to Sustainable Solutions in the UAE
[Picked up by 290 media titles]
2024-12-18 15:35
Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
8585
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
8275
